Yosuke Kito

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 7

Top Venues

The oncologist

Japanese journal of clinical oncology

Cancer chemotherapy and pharmacology

International journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, Masashi Fujii
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08). The oncologist 29 (8) (2024)
Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, Masashi Fujii
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08). The oncologist (2024)
Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, Masashi Fujii
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08). The oncologist 29 (8) (2024)
Atsuo Takashima, Megumi Ishiguro, Keita Sasaki, Ryunosuke Machida, Fumio Nagashima, Jun Imaizumi, Tetsuya Hamaguchi, Yoshiyuki Yamamoto, Toshiki Masuishi, Masako Asayama, Hideki Ueno, Katsunori Shinozaki, Toshihiro Kudo, Nozomu Machida, Hiroshi Matsuoka, Hideyuki Ishida, Toshifumi Yamaguchi, Hitoshi Nogami, Takeshi Yamada, Naoki Takegawa, Yosuke Kito, Yuko Tonoike, Ryoichi Sawada, Shunsuke Tsukamoto, Yukihide Kanemitsu, null null
Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group. Japanese journal of clinical oncology (2024)
Yosuke Kito, Hiasto Kawakami, Seiichiro Mitani, Shinichi Nishina, Toshihiko Matsumoto, Takao Tsuzuki, Yudai Shinohara, Hozumi Shimokawa, Ryosuke Kumanishi, Takashi Ohta, Hiroo Katsuya, Takeshi Kawakami, Tomohiro Nishina, Hiroko Hasegawa, Kohei Akiyoshi, Yasutaka Chiba, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). The oncologist (2023)
Yosuke Kito, Hironaga Satake, Hiroya Taniguchi, Takeshi Yamada, Yoshiki Horie, Taito Esaki, Tadamichi Denda, Hisateru Yasui, Naoki Izawa, Toshiki Masuishi, Toshikazu Moriwaki, Keita Mori, Kentaro Yamazaki
Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer. Cancer chemotherapy and pharmacology 86 (2) (2020)
Yosuke Kito, Nozomu Machida, Sadayuki Kawai, Satoshi Hamauchi, Takahiro Tsushima, Akiko Todaka, Tomoya Yokota, Kentaro Yamazaki, Akira Fukutomi, Yusuke Onozawa, Kunihiro Tsuji, Hisashi Doyama, Yutaka Haraguchi, Koji Nakashima, Kenji Kunieda, Keisei Taku, Keita Mori, Hirofumi Yasui
Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer. International journal of clinical oncology 23 (6) (2018)

Yosuke Kito.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yosuke Kito